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Copyright © 2005 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.07.011Objective: Reoperations are associated with an increased surgical risk due to
adhesions. We prospectively evaluated a bioresorbable membrane after surgery for
congenital heart defects over a 3.5-year period.
Methods: The surgical membrane (CV Seprafilm, Genzyme, Cambridge, Mass) was
applied in 350 of 1024 patients; 30 of them underwent reoperation and were
evaluated in comparison to 10 random reoperated patients. Adhesions were evalu-
ated using a subjective scoring system [1 (lowest tenacity) to 5 (highest tenacity)]
and extent in percent at different regions of the heart.
Results: Patients were operated for atrioventricular septal defect (69), tetralogy of
Fallot (65), functional single ventricle (75), valve surgery (48), ventricular septal
defect (20), subaortic stenosis (17), hypoplastic left heart syndrome (17), and other
diagnoses (39). Application of the surgical membrane was safe in all patients,
without any infections. At reoperation patients received Glenn (14), total cavopul-
monary connection (6), and others (10). Overall mortality was 2/350 (0.57%). There
was a remarkable reduction in tenacity score (3.3 vs 4.3) and in the extent of
adhesions (77.7% vs 86%). Duration of reoperation was significantly reduced.
Conclusions: A bioresorbable surgical membrane leads to a significant reduction in
the tenacity and amount of adhesions. It is recommended for general use whenever
repeat operation is anticipated in congenital as well as in adult cardiac surgery.
Congenital cardiac surgery is characterized by an increasing numberof patients receiving early complete corrections. Others can besafely operated on by staged approaches. In both groups reopera-tions may be required. Patients with univentricular physiologyreceive several surgical procedures during the first years of life.Others, for example patients after surgical correction for tetralogy
of Fallot (TOF), may require reoperation of the right ventricular outflow tract
(RVOT) later in life.
Any reoperation in congenital or adult cardiac surgery imposes an increased
surgical risk onto the individual patient. This increased risk is mostly caused by the
occurrence of surgical adhesions. Adhesions lead to more difficult sternal reentry
and cardiac dissection, to blunted visibility of distinct cardiac structures, to potential
injury of cardiac structures (including the atria, ventricles, and coronary arteries), as
well as to an increased risk of surgical bleeding, all associated with an increase in
morbidity and mortality. Furthermore, reoperations due to adhesions are more
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Dtime-consuming, and because of the increased difficulty
they are associated with a greater level of stress for the
individual surgeon.
No effective means to prevent such adverse adhesions
are available at present. Direct closure of the autologous
pericardium is possible in a small number of young patients
only. This is due to the fact that in the majority of patients
autologous pericardium is excised to be used for surgical
corrections (eg, ventricular septal defect closure, atrioven-
tricular septal defect [AVSD] repair, or RVOT patch en-
largement procedures). Use of surgical membranes (eg,
polytetrafluoroethylene [PTFE]; Gore-Tex, W. L. Gore &
Associates, Inc, Flagstaff, Ariz) has clearly led to facilitated
sternal reentry. However, intrapericardial adhesions still are
substantive in most patients. A bioresorbable material
would theoretically allow safe sternal closure with the later
development of a free dissection plane for any reoperation.
Restoring a plane by applying a film between the heart and
surrounding tissues may improve cardiac function and sim-
plify access on a future occasion.
We prospectively evaluated a resorbable membrane over
a 3.5-year period. Results on 350 patients as well as 30
reoperations are presented and discussed.
Materials and Methods
Patients
From September 2000 until February 2004 a total of 1024 patients
TABLE 1. Number of pediatric cardiac operations for indi-
vidual patients as well as use of the adhesion barrier and
mortality during the 3.5-year period in a tertiary care center
Pediatric cardiac
operation for the
individual patient n
Mortality,
n (%)
Use of
adhesion
barrier (n)
Mortality,
n (%)
Primary 744 8 (1.1%) 190 1 (0.5%)
First reoperation 198 4 (2%) 108 1 (0.9%)
Second reoperation 66 1 (1.5%) 39 —
Third reoperation 13 — 10 —
Fourth reoperation 3 — 3 —
Total 1024 13 (1.3%) 350 2 (0.57%)
TABLE 2. Palliative pediatric cardiac operations for the
individual patients as well as use of the adhesion barrier
during the 3.5-year period in a tertiary care center
Palliative pediatric
cardiac operation n
Use of adhesion
barrier (n)
Primary 95 49
Secondary 49 34
Tertiary 7 2
Total 161 85underwent correction for congenital cardiac malformations at our
360 The Journal of Thoracic and Cardiovascular Surgery ● Febrhospital; 350 of those, all potential candidates for repeat surgical
intervention, received artificial pericardial closure during this time
interval. This included patients with planned staged procedures,
with potential reoperations on the RVOT, with valve reconstruc-
tions (eg, AVSD correction), or with other complex cardiac mal-
formations. Thirty of these patients underwent reoperations with
repeat cardiac dissection during the study period, most of them for
planned staged procedures. Patients with primary total correction
in whom no repeat intervention was anticipated were not included
in the study. The patient subset is depicted in Table 1, which shows
the type of operation as well as mortality. Palliative operations are
depicted in Table 2. This is a prospective evaluation study, per-
formed under institutional review board protocol. Repeat sternot-
omy was performed with an oscillating saw in all patients.
Adhesion Barrier
A sterile and bioresorbable translucent membrane (CV Seprafilm,
Genzyme, Cambridge, Mass) composed of US Pharmacopeia glyc-
erol and 2 chemically modified anionic polysaccharides, sodium
hyaluronate and carboxymethylcellulose, was used. The size of the
membrane was approximately 12 12 cm. The CV Seprafilm was
packed in a Tyvek holder (DuPont, Wilmington, Del). This al-
lowed cutting or other manipulations of the membrane without
disruption due to sticking to unintended places. The membrane
was handled in a dry fashion, with dry gloves, a dry gauze, or clean
forceps. Application was performed just before sternal closure to
the dry mediastinum. The membrane was taken off the holder and
applied to the intended tissue. If the membrane stuck to unintended
places, it could eventually be removed after careful rinsing with a
standard irrigating solution. Depending on patient size, 1 (suffi-
cient in most pediatric operations) or 2 membranes were applied.
The CV Seprafilm has been approved for clinical use.
Measurements
Application of the CV Seprafilm surgical membrane as well as
eventual sternal reentry were evaluated according to a subjective
rating scale filled out by the surgeon: Application was judged as
easy handling without complications covering the whole heart,
moderately easy handling covering the anterior aspect of the heart
only, difficult handling due to unintended adhesion of the mem-
brane, and difficult handling necessitating use of another package
of the membrane.
Each adhesion was judged according to its tenacity and its
extension and according to the percentage of the specific cardiac
region covered. For both the evaluation of tenacity and extension
of adhesions during sternal reentry and cardiac redissection, the
following different regions were evaluated: The anterior or retro-
sternal region (A), the inferior or diaphragmatic region (B), the
right lateral or atrial region (C), the region around the great vessels
(D), and the left lateral or ventricular region (E); furthermore, an
overall evaluation was performed (F).
In these different areas the tenacity of adhesions was judged as
none (1), filmy requiring blunt dissection (2), moderate requiring
blunt and sharp dissection (3), dense requiring sharp dissection (4),
or very dense requiring extensive sharp dissection (5). This eval-
uation was performed according to a previous study with slightly
modified rating.1 Two surgeons took part in this study in a non-
blinded fashion.
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DPatient Evaluation
Follow-up of all patients is routinely performed at the outpatient
clinic. This guarantees that all candidates for repeat surgical inter-
vention will be followed up and repeat interventions performed at
our hospital. Results of the patients receiving repeat operations
after using the adhesion barrier were compared to 10 random
patients receiving repeat interventions without use of a specific
adhesion barrier. These patients received Glenn (5), total cavopul-
monary connection (2), corrections for RVOT obstructions (2),
and repeat intervention for AVSD (1).
All data are expressed as mean standard deviation. Statistical
analysis between groups was performed by the Wilcoxon test for
unmatched pairs when appropriate.
Results
Of the total of 350 patients receiving the CV Seprafilm, 30
patients required reoperation throughout the study period
and were evaluated.
The types of operations for the 350 patients are given in
Table 3. Overall mortality was 2 (0.57%) of 350 throughout
the study period. One neonate with complex cardiac anat-
omy died after primary operation, receiving a modified
Blalock-Taussig shunt and pulmonary artery banding; the
other died after Norwood II procedure with additional liga-
tion of major aortopulmonary collateral arteries after reop-
eration. All other patients were discharged from the hospital
and there was no mortality during follow-up.
There were no mediastinal infections throughout the
study period. Even at delayed sternal closure (n  17
patients in this study), the surgical membrane was safely
applied without any further problems.
At repeat sternotomy landmarks and epicardial coronary
vessels were not as indistinct as when using a PTFE mem-
brane. However, visibility was different from primary op-
erations. Adhesions were reduced wherever the absorbable
membrane had been placed. In this study there was no
relation between elapsed time since initial operation and the
ease of reoperation. We did not see any impact on bleeding
and transfusion requirement.
Application of the membrane was feasible in all patients.
It was judged as easy without complications covering the
whole heart in 63.7%, moderately easy covering the anterior
aspect of the heart only in 29.7%, difficult due to unintended
adhesion of the membrane in 5.1%, and difficult necessitat-
ing use of another package of the membrane in 1.4% of the
patients, respectively. After initial experience had been
gained, it was more easily accomplished throughout the
study. Initially the membrane was positioned anteriorly
only; after some experience with reoperations, it was also
positioned around the heart. This led to a lesser degree of
tenacity of the adhesions in most lateral and inferior parts
and to easier repeat thoracotomy.
In the 30 patients with reoperations, the time between
initial operation and repeat intervention was 12.7  12.2
The Journal of Thoracimonths (range 1-41 months). Reoperations are listed in
Table 4. The adhesion barrier led to a subjective but re-
markable facilitation of surgical repeat intervention due to a
decrease in tenacity and extent of adhesions and thus an
easier repeat thoracotomy. Results on the subjective tenac-
ity scoring are given in Figure 1. Results on the extent of
surgical adhesions in the different areas as well as on the
duration between incision and start of extracorporeal circu-
lation are given in Figure 2. Overall, the surgeons felt much
more comfortable performing a reoperation in the presence
of the adhesion barrier. They judged its presence as a
clinically relevant benefit, rendering the reoperation easier
and leading to an increased safety for the patient.
Discussion
Adhesions after cardiac operations lead to an increased risk
Table 3. Primary operations for the 350 patients receiving
the adhesion barrier
Primary operation n
Atrial and atrioventricular septal defect repair 69
Tetralogy of Fallot and pulmonary atresia repair 65
Functional single ventricle procedures
Shunt 28
Glenn 27
TCPC 16
Pulmonary artery banding 4
Valve surgery (aortic, mitral, pulmonary) 48
Switch operation 5
VSD, closure 20
Subaortic stenosis resection 17
Norwood I 17
Persistent truncus arteriosus repair 6
Rastelli 5
Other 23
TCPC, Total cavopulmonary connection; VSD, ventricular septal defect.
Table 4. Reoperations performed in 30 patients (mean in-
terval between primary and secondary operation was 12.7
 12.2 months)
Reoperations n
Glenn 14
TCPC 6
Multiple VSD closure 2
Correction for AVSD plus tetralogy of Fallot 2
Correction for RVOT stenoses 2
Rastelli repair 1
Switch 1
Other 2
TCPC, Total cavopulmonary connection; VSD, ventricular septal defect;
AVSD, atrioventricular septal defect; RVOT, right ventricular outflow tract.and difficulty of surgical repeat intervention. Optimal mea-
c and Cardiovascular Surgery ● Volume 129, Number 2 361
Surgery for Congenital Heart Disease Walther et al
CH
Dsures to prevent adhesions are not available at present.
Direct closure of the patient’s own pericardium may lead to
a lesser extent of adhesions and to easier sternal reentry.
However, it is not feasible in most patients undergoing
congenital cardiac surgery, because the autologous pericar-
dium is partially being used for surgical correction.
Different techniques to replace the pericardium as well as to
potentially decrease the tenacity and the amount of adhesions
have been applied as documented in the literature. However,
no definitive method has yet evolved. Different techniques
such as PTFE membranes,2-4 sprayable polymeric matrices,1,5
hydrophilic polymeric solutions,6 hyaluronic acid films or cel-
lulose,7-9 bioresorbable membranes,10 hydrogel derivates,11
polymer films,12 and medical anti-inflammatory therapy13
have been published. However, none of these approaches has
proven optimal effectiveness. Thus, there is still need for a
universal, safe, effective, and easy-to-use material to signifi-
cantly reduce surgical adhesions. This would be extremely
Figure 1. Intensity of adhesions according to the subjective te-
nacity scoring for 30 study patients (CV Seprafilm) in comparison
with 10 random control patients. Adhesions are evaluated ac-
cording to different areas during repeat cardiac dissection. See
text for further definition of the score.
Figure 2. Extent of adhesions as judged by the percentage of the
different areas covered as well as duration between skin incision
and start of extracorporeal circulation for 30 study patients (CV
Seprafilm) in comparison with 10 random control patients. *P <
.05.helpful in cardiac as well as general surgery repeat procedures.
362 The Journal of Thoracic and Cardiovascular Surgery ● FebrUse of a hyaluronic acid carboxymethylcellulose bioresorbable
membrane (Seprafilm) has been shown to be effective in
abdominal surgery.14
Application of the resorbable membrane was feasible
throughout our study. However, the membrane should be
handled with dry hands only and disruption may occur after
unforeseen contact with parts of the open chest. After some
experience application as such is easy. However, a spray-
able substance would probably be even easier to handle.
According to our results the CV Seprafilm resorbable
membrane has proven effectiveness in reducing the tenacity
as well as the extent of surgical adhesions. This leads to a
relevant facilitation of any reoperation as documented by a
significantly shorter duration between incision and start of
extracorporeal circulation. The membrane is applicable for
both pediatric and adult cardiac surgical patients; in the
latter, a slightly larger package would be favorable. In all
instances use of such a membrane leads to a relevant reduc-
tion in the risk of repeat surgical thoracotomy and thus is of
clinical benefit for the individual patient.
We did not perform a blinded randomized trial, which
would be superior in demonstrating the clinical benefit of a
new bioresorbable membrane. However, diagnoses as well
as the potential amount, tenacity, and formation of adhe-
sions differ between individual patients. Thus, a randomized
trial would only partially offer more reliable clinical results.
Due to the variability in diagnoses as well as to the fact that
we initially evaluated the usefulness of the new product, we
did not perform a randomized trial.
A combination of using a resorbable membrane together
with a PTFE membrane would eventually be of additional
benefit. However, with the resorbable membrane a sufficient
plane for safe sternal reentry is usually present as seen in
our study. Additional PTFE, therefore, is not required.
Whenever sufficiently available, we would close the autol-
ogous pericardium and place parts of the resorbable mem-
brane below as well as above.
As shown in Table 3 we see an indication for using such
an adhesion barrier in all patients receiving planned staged
approaches (functional single ventricle palliation or Nor-
wood procedures) as well as in those eventually requiring
repeat intervention. This includes all patients receiving
valve reconstructions (AVSD repair, single or combined
valve surgery) as well as TOF repair. Few patients receiving
total corrections (eg, switch operation) are candidates for
using an adhesion barrier.
Is there an indication to use such a membrane in all
patients receiving cardiac surgery? In terms of facilitated
repeat thoracotomy there would be a clear benefit. Patients
in whom any repeat intervention may be required in due
course, approximately within the following 1 to 5 years, will
clearly benefit. At present, we cannot foresee whether it
would be advantageous for all patients, even for pediatric
uary 2005
Walther et al Surgery for Congenital Heart Disease
CH
Dpatients who may require coronary or valve surgery much
later in life. As there was no increased risk and especially no
incidence of mediastinitis from using the membrane, there is
no disadvantage when using it in every patient.
The cost-effectiveness has to be considered as well. Ease
and reduced duration of repeat surgical procedures will
always justify the use of the membrane. Sometimes it will
be difficult to exactly foresee which patient will require
reoperation. However, general use of a bioresorbable mem-
brane may be restricted due to financial issues.
In summary, excellent intermediate-term results were
demonstrated after using a bioresorbable surgical membrane
in selected patients receiving congenital cardiac surgical
operations. A clinically relevant reduction in the tenacity as
well as the overall extent of adhesions was proven. This
results in a significant reduction of reoperative risk and a
benefit for the individual patient.
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